Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424288 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
A Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 6,000
- Enrollment target
- 20
- Study locations
NCT06424288 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 6,000 participants, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06424288, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 6,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.
Conditions Studied
Interventions
- DRUG placebo
- DRUG vicadrostat
- DRUG empagliflozin
Study Locations (20)
Florida
- Excel Medical Clinical Trials - Boca Raton
- Bay Area Cardiology - Brandon
- Clearwater Cardiovascular and Interventional Consultants - Clearwater
- Cardiology Associates Research Co. - Daytona Beach
- Malcom Randall VA Medical Center - Gainesville
- Velocity Clinical Research-Hallandale Beach-67888 - Hallandale
- University of Florida Health Jacksonville - Jacksonville
- East Coast Institute for Research, LLC - Jacksonville - Jacksonville
- East Coast Institute for Research, LLC - Jacksonville - Jacksonville
- First Coast Cardiovascular Institute - Jacksonville
- Clearwater Cardiovascular Consultants-Largo-69917 - Largo
- University of Miami - Miami
California
- Velocity Clinical Research-Chula Vista - Chula Vista
- University of California Irvine - Orange
- North America Research Institute - San Dimas
- Amicis Research Center - Valencia - Santa Clarita
- Orange County Research Center - Tustin
Alabama
- Diagnostic and Medical Clinic - Mobile
- Mobile Heart Specialists, PC - Mobile
Connecticut
- Bridgeport Hospital - Bridgeport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2028-05-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06424288
The ClinicalTrials.gov registry entry for NCT06424288 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,034-participant average among 397 other Heart Failure trials with a reported enrollment target (195% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT06424288 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06424288 about?
NCT06424288 is a clinical study titled "A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure". This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empag...
What is the current status of trial NCT06424288?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 6,000 participants. The study started on 2024-06-17. Estimated completion is 2028-05-22.
What conditions does trial NCT06424288 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06424288?
The interventions under investigation include: placebo (DRUG), vicadrostat (DRUG), empagliflozin (DRUG).
Who is sponsoring clinical trial NCT06424288?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06424288 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.